UK Genetic Prostate Cancer Study: Epidemiology and Molecular Genetics Studies

NCT01737242 | Active Not Recruiting DMC

• 2 other identifiers: 06/MRE02/4CCR0848
• Study Type: observational
• Target: 23,826
• Locations: 1 country
• Sites: 1

Brief Summary

The UKGPCS was set up to find genetic alterations which occur in patients who have prostate cancer. A man's risk of developing prostate cancer increases if he has a first-degree relative (father or brother) who was diagnosed with prostate cancer at a young age. This is why we are looking for men who are affected at a young age or who have a family history of prostate cancer, since it is more probable that these prostate cancers are due to an inherited genetic cause rather than an environmental cause. We also ask all men who come to the Royal Marsden Hospital to be treated for prostate cancer if they would like to take part in the study so that we can also look to see if we find genetic alterations in older men, and those who do not have a family history of prostate cancer.

Conditions

Prostate Cancer

Keywords

Prostate cancer; PSA

Outcome Measures

Primary Outcomes (1)

• To find genes which predispose to PrCa

  2017

Eligibility Criteria

• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Any patients that meets the eligibility criteria and may be attending a hospital that have got ethical approval.

You may qualify if:

• Man with PrCa at any age at diagnosis at Royal Marsden NHS Foundation Trust
• Those outside the Royal Marsden NHS Foundation Trust with
• PrCa at or below 60 years at diagnosis
• PrCa in first-degree related pairs where one is ≤ 65 years at diagnosis
• PrCa at any age in a cluster with 3 or more cases
• Those able to understand the information sheet and give informed consent (language line is available for those who wish to have translation)
• Any unaffected relatives of men who are already taking part in the study

You may not qualify if:

• Man with PrCa who is too ill to take part

Sponsors & Collaborators

• Institute of Cancer Research, United Kingdom: lead
• Cancer Research UK: collaborator
• Royal Marsden NHS Foundation Trust: collaborator

Study Sites (1)

Institute of Cancer Research and Royal Marsden Hospital

Sutton, Surrey, SM2 5GP, United Kingdom

Location

Related Publications (1)

• Kote-Jarai Z, Mikropoulos C, Leongamornlert DA, Dadaev T, Tymrakiewicz M, Saunders EJ, Jones M, Jugurnauth-Little S, Govindasami K, Guy M, Hamdy FC, Donovan JL, Neal DE, Lane JA, Dearnaley D, Wilkinson RA, Sawyer EJ, Morgan A, Antoniou AC, Eeles RA; UK Genetic Prostate Cancer Study Collaborators, and the ProtecT Study Group. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. Ann Oncol. 2015 Apr;26(4):756-761. doi: 10.1093/annonc/mdv004. Epub 2015 Jan 16.

  PMID: 25595936 DERIVED

Related Links

• Study Website

Biospecimen

Retention: SAMPLES WITH DNA

Whole blood, Prostate Tissue, saliva samples

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Officials

• Rosalind A Eeles, FRCP FRCR

  Institute of Cancer Research and Royal Marsden Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 27, 2012
• First Posted: November 29, 2012
• Study Start: January 1, 1993
• Primary Completion: November 1, 2023
• Study Completion (Estimated): December 31, 2027
• Last Updated: February 4, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will share

Locations

GB (1)